These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29463898)

  • 1. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.
    Du X; Liu M; Su J; Zhang P; Tang F; Ye P; Devenport M; Wang X; Zhang Y; Liu Y; Zheng P
    Cell Res; 2018 Apr; 28(4):433-447. PubMed ID: 29463898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
    Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
    Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.
    Zhang Y; Du X; Liu M; Tang F; Zhang P; Ai C; Fields JK; Sundberg EJ; Latinovic OS; Devenport M; Zheng P; Liu Y
    Cell Res; 2019 Aug; 29(8):609-627. PubMed ID: 31267017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
    Perez-Ruiz E; Minute L; Otano I; Alvarez M; Ochoa MC; Belsue V; de Andrea C; Rodriguez-Ruiz ME; Perez-Gracia JL; Marquez-Rodas I; Llacer C; Alvarez M; de Luque V; Molina C; Teijeira A; Berraondo P; Melero I
    Nature; 2019 May; 569(7756):428-432. PubMed ID: 31043740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment.
    Lisi L; Lacal PM; Martire M; Navarra P; Graziani G
    Pharmacol Res; 2022 Jan; 175():105997. PubMed ID: 34826600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
    Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
    Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
    J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
    Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid disorders induced by checkpoint inhibitors.
    Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
    Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.
    Liu Y; Zheng P
    Trends Pharmacol Sci; 2020 Jan; 41(1):4-12. PubMed ID: 31836191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers associated with checkpoint inhibitors.
    Manson G; Norwood J; Marabelle A; Kohrt H; Houot R
    Ann Oncol; 2016 Jul; 27(7):1199-206. PubMed ID: 27122549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.
    Brunner-Weinzierl MC; Rudd CE
    Front Immunol; 2018; 9():2737. PubMed ID: 30542345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage
    Duperret EK; Trautz A; Stoltz R; Patel A; Wise MC; Perales-Puchalt A; Smith T; Broderick KE; Masteller E; Kim JJ; Humeau L; Muthumani K; Weiner DB
    Cancer Res; 2018 Nov; 78(22):6363-6370. PubMed ID: 30287678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.
    Zhao Y; Yang W; Huang Y; Cui R; Li X; Li B
    Cell Physiol Biochem; 2018; 47(2):721-734. PubMed ID: 29794465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
    Kumar P; Bhattacharya P; Prabhakar BS
    J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.